Israel Englander’s Bicara Therapeutics BCAX Stock Holding History

Israel Englander’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.79M	Buy	262,254 +105,552	+67%	+$2.36M	﹤0.01%	2562
2026 Q1	$3.12M	Sell	156,702 -277,997	-64%	-$4.79M	﹤0.01%	3434
2025 Q4	$7.32M	Sell	434,699 -580,193	-57%	-$9.91M	﹤0.01%	2595
2025 Q3	$16M	Buy	1,014,892 +273,873	+37%	+$3.07M	0.01%	1917
2025 Q2	$6.88M	Buy	741,019 +715,371	+2,789%	+$8.53M	﹤0.01%	2642
2025 Q1	$334K	Sell	25,648 -359,758	-93%	-$4.78M	﹤0.01%	5040
2024 Q4	$6.71M	Buy	385,406 +85,847	+29%	+$1.79M	﹤0.01%	2551
2024 Q3	$7.63M	Buy	+299,559	New	+$7.64M	﹤0.01%	2445

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's BCAX Position: Q2 2026 in Review

Israel Englander increased its Bicara Therapeutics (BCAX) stake by 67% in Q2 2026, buying an estimated $2.36M and bringing the position to 262,254 shares worth $7.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2562.

Israel Englander first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $16M in Q3 2025. 170 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

Israel Englander held 262,254 shares of Bicara Therapeutics worth $7.79M as of Q2 2026.
Israel Englander bought 105,552 Bicara Therapeutics shares in Q2 2026, an estimated $2.36M.
Bicara Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2562 holding.
Israel Englander first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
Israel Englander's Bicara Therapeutics position peaked at $16M in Q3 2025.
170 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.